To assess demographic and clinical characteristics, medication use patterns, and symptom/PRO tracking in users of the Tami app for IBD management from June 2023 to December 2024.
Approach:
Key Findings:
Users can track symptoms and PROs, monitor medication use, and receive personalized health guidance, which is crucial for understanding IBD progression.
The app allows for real-time data collection, essential for understanding IBD progression.
Interpretation:
The Tami app serves as a valuable tool for IBD patients, facilitating personalized management and enhancing understanding of their condition through continuous data tracking and tailored health insights.
Limitations:
The study is limited to users who consented to data sharing, which may not represent the entire IBD population.
Data is self-reported, which may introduce bias or inaccuracies.
Potential technological barriers may limit participation and data accuracy.
Conclusion:
The baseline assessment of Tami users will support future analyses linking symptoms with disease activity and treatment responses, ultimately aiding in personalized treatment strategies and improving patient outcomes.
